198 related articles for article (PubMed ID: 34294688)
1. Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells.
Karakas B; Aka Y; Giray A; Temel SG; Acikbas U; Basaga H; Gul O; Kutuk O
Cell Death Discov; 2021 Jul; 7(1):189. PubMed ID: 34294688
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy.
Kawiak A; Kostecka A
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053443
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
Ahn S; Park JH; Grimm SL; Piyarathna DWB; Samanta T; Putluri V; Mezquita D; Fuqua SAW; Putluri N; Coarfa C; Kaipparettu BA
Cancer Res; 2024 Jan; 84(2):291-304. PubMed ID: 37906431
[TBL] [Abstract][Full Text] [Related]
5. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
6. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
Yang Z; Barnes CJ; Kumar R
Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
[TBL] [Abstract][Full Text] [Related]
9. Breast Cancer-Stromal Interactions: Adipose-Derived Stromal/Stem Cell Age and Cancer Subtype Mediated Remodeling.
Hamel KM; King CT; Cavalier MB; Liimatta KQ; Rozanski GL; King TA; Lam M; Bingham GC; Byrne CE; Xing D; Collins-Burow BM; Burow ME; Belgodere JA; Bratton MR; Bunnell BA; Martin EC
Stem Cells Dev; 2022 Oct; 31(19-20):604-620. PubMed ID: 35579936
[TBL] [Abstract][Full Text] [Related]
10. FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.
Castillo-Castrejon M; Sankofi BM; Murguia SJ; Udeme AA; Cen HH; Xia YH; Thomas NS; Berry WL; Jones KL; Richard VR; Zahedi RP; Borchers CH; Johnson JD; Wellberg EA
Breast Cancer Res; 2023 Aug; 25(1):99. PubMed ID: 37608351
[TBL] [Abstract][Full Text] [Related]
11. Estrogen regulation and functional role of FGFR4 in estrogen receptor positive breast cancer.
Ding K; Chen L; Levine K; Sikora M; Tasdemir N; Dabbs D; Jankowitz R; Hazan R; Shah OS; Atkinson JM; Lee AV; Oesterreich S
bioRxiv; 2024 Mar; ():. PubMed ID: 38562741
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
13. Mouse models of estrogen receptor-positive breast cancer.
Mohibi S; Mirza S; Band H; Band V
J Carcinog; 2011; 10():35. PubMed ID: 22279420
[TBL] [Abstract][Full Text] [Related]
14. Mouse ER+/PIK3CA
Stratikopoulos EE; Kiess N; Szabolcs M; Pegno S; Kakit C; Wu X; Poulikakos PI; Cheung P; Schmidt H; Parsons R
Oncogene; 2019 Jan; 38(1):47-59. PubMed ID: 30076411
[TBL] [Abstract][Full Text] [Related]
15. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
16. Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
Padró M; Louie RJ; Lananna BV; Krieg AJ; Timmerman LA; Chan DA
BMC Cancer; 2017 Mar; 17(1):203. PubMed ID: 28320353
[TBL] [Abstract][Full Text] [Related]
17. Endocrine therapy--current benefits and limitations.
Nicholson RI; Johnston SR
Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.
Zhao M; Ramaswamy B
World J Clin Oncol; 2014 Aug; 5(3):248-62. PubMed ID: 25114842
[TBL] [Abstract][Full Text] [Related]
19. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
20. microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy.
Howard EW; Yang X
Biol Proced Online; 2018; 20():17. PubMed ID: 30214383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]